02/16/2025, 05:02 AM UTC
诺华：强劲执行与市盈率折让Novartis: Strong Execution With A P/E Discount
1、诺华2024年第四季度业绩超出预期，净销售额增长16%，营业收入增长55%；2、收购Anthos Therapeutics和研发领域的战略投资支持诺华在创新药物领域的领导者地位；3、诺华强劲的自由现金流生成能力、支持性的股息收益率以及持续的回购使其成为一项有吸引力的投资。1. Novartis' Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income; 2. The acquisition of Anthos Therapeutics and strategic investments in R&D support Novartis' position as a leader in innovative medicines; 3. Novartis' strong free cash flow generation, supportive dividend yield, and ongoing buyback make it an attractive investment.---
本文由大语言模型（LLM）生成，旨在为读者提供半导 体新闻内容的知识扩展（Beta）。
